Case Reports in Dermatological Medicine最新文献_第3页

Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib. 白发症相关指甲变化对巴利替尼的治疗反应

Case Reports in Dermatological Medicine Pub Date : 2024-08-31 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8879884

Ashley Wittmer, Katherine De Jong, Lauren Bolish, Lindsey Finklea

{"title":"Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib.","authors":"Ashley Wittmer, Katherine De Jong, Lauren Bolish, Lindsey Finklea","doi":"10.1155/2024/8879884","DOIUrl":"10.1155/2024/8879884","url":null,"abstract":"Nail changes are seen in some individuals with alopecia areata, with the most common variants including pitting and trachyonychia. The nail findings are presumed to be due to the same lymphocytic infiltration seen in hair bulbs in individuals with AA. Baricitinib is an immunomodulatory drug that acts as a selective and reversible inhibitor of JAK proteins and is indicated for adult patients with moderate to severe rheumatoid arthritis who have not responded to other disease-modifying antirheumatic drugs. The FDA has also approved baricitinib to treat patients hospitalized with COVID-19 and severe alopecia areata. In this report, we present a case of a patient with persistent AA-associated nail changes who has been successfully treated with baricitinib. The patient has been suffering from alopecia for several years. She presented with periungual inflammation in conjunction with persistent fingernail ridges and pitting of her right fourth digit. The nail dystrophy persisted despite treatment with tacrolimus ointment, clobetasol ointment, or oral fluconazole. Patient was started on a trial of baricitinib for alopecia areata, which was the suspected cause of the nail changes. After 4 months of treatment with baricitinib, the patient's nail showed mild improvement of nail dystrophy with some clubbing and pitting still present. Within 11 months of treatment, her nail was normalized in appearance and texture. There are no established guidelines to treat AA-associated nail changes. Our patient's AA-associated nail changes were normalized after 11 months of treatment with baricitinib. Further research is needed to determine which alopecia areata patients may benefit from treatment with baricitinib and when treatment should be initiated. Baricitinib may be an effective treatment option for AA-associated nail changes in some patients.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"2024 ","pages":"8879884"},"PeriodicalIF":0.0,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome on the Basis of Selective IgA Deficiency. 基于选择性 IgA 缺乏症的成人周期性发热、口腔炎、咽炎和宫颈腺炎综合征

Case Reports in Dermatological Medicine Pub Date : 2024-07-31 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9845501

Seda Altiner, Alper Ekinci

{"title":"Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome on the Basis of Selective IgA Deficiency.","authors":"Seda Altiner, Alper Ekinci","doi":"10.1155/2024/9845501","DOIUrl":"10.1155/2024/9845501","url":null,"abstract":"Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome (PFAPA) is an autoinflammatory disease that is thought to occur with the contribution of genetic and environmental factors, but its etiology has not been clearly elucidated. It is characterized by recurrent attacks with fever, pharyngitis, oral aphthous lesions, and cervical lymphadenopathy, and an increase in the level of serum acute phase reactants is observed during the attacks. Although PFAPA usually begins in childhood, adult-onset cases are also reported in the literature. In the pathogenesis of PFAPA, an increase in the expression of various inflammatory cytokines, especially interleukin-1β (IL-1β), is observed as a result of the increase in inflammasome activity. Selective IgA deficiency (SIgAD) is the most prevalent primary immunodeficiency. Although most SIgAD cases remain asymptomatic and remain undiagnosed, it is known that the risk of mucosal infection is generally increased in SIgAD cases. In addition, the frequency of autoinflammatory diseases is increased in SIgAD cases compared with the general population. We aim to present a case of adult-onset PFAPA and SIgAD coexistence.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"2024 ","pages":"9845501"},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis. 成功使用杜匹单抗治疗特应性皮炎相关的获得性穿孔性皮肤病。

Case Reports in Dermatological Medicine Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6265608

Niccolò Gori, Eleonora De Luca, Andrea Chiricozzi, Stefania Sfregola, Alessandro Di Stefani, Ketty Peris

{"title":"Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis.","authors":"Niccolò Gori, Eleonora De Luca, Andrea Chiricozzi, Stefania Sfregola, Alessandro Di Stefani, Ketty Peris","doi":"10.1155/2024/6265608","DOIUrl":"10.1155/2024/6265608","url":null,"abstract":"Acquired reactive perforating collagenosis is a rare cutaneous disorder characterised by the extrusion of abnormal connective tissue trough epidermidis and/or follicular units. Reactive perforating collagenosis is often associated with systemic diseases in which pruritus is a common symptom (e.g., diabetes and chronic kidney disease). Less commonly, it has been associated with chronic inflammatory dermatoses, including atopic dermatitis, as in this case. In this report, we describe the exceptional case of a 35-year-old man affected by acquired reactive perforating collagenosis associated with atopic dermatitis who was resistant to conventional topical and systemic treatment and experienced complete resolution of clinical signs and symptoms after 12 weeks of treatment with dupilumab. In our patient, the severe pruritus induced by atopic dermatitis likely contributed to the development of acquired perforating collagenosis lesions, which are thought to be a reactive response to chronic scratching and repetitive injury to the skin. Chronic pruritus in atopic dermatitis is known to be driven by type 2 cytokines, including IL-4 and IL-13, and dupilumab, a monoclonal antibody inhibiting IL-4 and IL-13 signalling, has been shown to be effective in the treatment of moderate to severe atopic dermatitis as well as other type 2-driven pruritic dermatological conditions. This case supports the potential use of dupilumab for the treatment of reactive perforating dermatosis.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"2024 ","pages":"6265608"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib. 乌达帕替尼成功治疗难治性全身性环状肉芽肿

Case Reports in Dermatological Medicine Pub Date : 2024-06-05 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8859178

Alexis Coican, Abigail Meckley, Nathan Sagasser, Melinda Greenfield, Eingun James Song, Jessica El-Bahri

引用次数: 0

Reactive Angioendotheliomatosis in Association with Ulcerative Colitis. 与溃疡性结肠炎有关的反应性血管内皮瘤病

Case Reports in Dermatological Medicine Pub Date : 2024-05-29 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6505274

R Afiouni, G Abadjian, F Stephan

引用次数: 0

Granuloma after the Injection of Poly-D,L-Lactic Acid (PDLLA) Treated with Triamcinolone 注射聚-D,L-乳酸 (PDLLA) 并用曲安奈德治疗后出现的肉芽肿

Case Reports in Dermatological Medicine Pub Date : 2024-04-25 DOI: 10.1155/2024/6544506

Kateryn Michelle Perez Willis, Rosario Ramirez Galvez

{"title":"Granuloma after the Injection of Poly-D,L-Lactic Acid (PDLLA) Treated with Triamcinolone","authors":"Kateryn Michelle Perez Willis, Rosario Ramirez Galvez","doi":"10.1155/2024/6544506","DOIUrl":"https://doi.org/10.1155/2024/6544506","url":null,"abstract":"Biostimulators are the latest trends in cosmetic procedures, substances such as PDLLA are used to induce collagen synthesis by a subclinical inflammatory reaction. We are describing a granuloma-like reaction case presentation 4 months after the application of PDLLA and its complete resolution with injections of triamcinolone. A 45-year-old female with any past medical history of allergies or immune diseases was injected with PDLLA on the mandibular border and cheek area to correct skin laxity. Four months after the application, the patient reported facial edema and granuloma-like reactions according to clinical examination on all the application areas. The ultrasound reports showed the presence of multiple nodules in the injection areas; therefore, we decided to apply triamcinolone to the granulomatous reaction areas 2 times a month and Prednisone 20 mg daily for 3 days followed by 10 mg for 2 days. After 4 applications, the adverse reaction was completely solved. Biostimulators are biocompatible and resorbable substances; however, nodules and/or granulomas have been reported as rare adverse events. Intralesional and oral steroids can allow us to treat this kind of adverse events.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"10 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Subcorneal Pustular Dermatosis without Dapsone: A Case Report and Review of the Literature 不使用达哌酮治疗角质层下脓疱性皮肤病：病例报告和文献综述

Case Reports in Dermatological Medicine Pub Date : 2024-04-02 DOI: 10.1155/2024/8140483

Lindsey J Wanberg, B. Schultz, A. Goyal

引用次数: 0

A Case of Diltiazem-Induced Pustular Rash in an 83-Year-Old Female 一名 83 岁女性的地尔硫卓诱发脓疱性皮疹病例

Case Reports in Dermatological Medicine Pub Date : 2024-04-02 DOI: 10.1155/2024/9547206

Ayrton I Bangolo, Karen Yelton-Torres, Atharv Mahajan, Vrushant Patel, Laiba Sajjad, Prince Ofori Ansong, Monisha Kashyap, Umesh Batura, Madhavi Ravulapalli, Ayodya Perera, Simcha I Weissman

引用次数: 0

A Saudi Woman with Ceftriaxone Induced Fixed Drug Eruption. 一名沙特妇女因头孢曲松诱发固定药物喷发。

Case Reports in Dermatological Medicine Pub Date : 2024-03-15 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9975455

Rehab Y Al-Ansari, Leena Abdulrahman Almuhaish, Khaled Abdullah Hassan, Tawasoul Fadoul, Alexander Woodman

{"title":"A Saudi Woman with Ceftriaxone Induced Fixed Drug Eruption.","authors":"Rehab Y Al-Ansari, Leena Abdulrahman Almuhaish, Khaled Abdullah Hassan, Tawasoul Fadoul, Alexander Woodman","doi":"10.1155/2024/9975455","DOIUrl":"10.1155/2024/9975455","url":null,"abstract":"Background: A fixed drug eruption (FDE) is an immunological cutaneous adverse reaction, classified as a cutaneous adverse drug reaction (CADR) and characterized by well-defined lichenoid lesions that occur at the same site each time. Ceftriaxone is a third-generation antibiotic of cephalosporin antibiotics of the beta-lactam antibiotic family, which has typical in vitro activity against many Gram-negative aerobic bacteria. This is the first clinical case from Saudi Arabia and the fifth in the world to document a woman's experience with recurrent FDE after repeated ceftriaxone use. Case Report. A 25-year-old Saudi woman with a known case of sickle cell anemia (SCA) with a history of avascular necrosis of the right hip after replacement was hospitalized with a pain crisis triggered by an upper respiratory tract infection. The patient denied having a history of allergy previously. Due to fever, leukocytosis, and active follicular tonsillitis, ceftriaxone was started. However, a few hours later she developed lip edema and a fixed drug eruption measuring 7 × 11 cm on the left side of her back. The lesion reformed over a hyperpigmented lesion (4 × 8 cm) that the patient did not report upon initial examination. It turned out that this was due to the intravenous administration of ceftriaxone, a year ago in another hospital. An allergy to ceftriaxone was considered, and steroids and antihistamines were started. The case was labeled as ceftriaxone induced FDE.Conclusion: Ceftriaxone induced FDE is an uncommon type of allergic reaction that has been reported infrequently. Understanding this condition and the mechanism by which FDE becomes recurrent with the same previous fixed lesion is of great importance for both academic and future research purposes.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"2024 ","pages":"9975455"},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sporadic Pemphigus Foliaceus in a 3-Year-Old Vietnamese Girl: A Case Report and Literature Review 一名 3 岁越南女孩的散发性丘疹性红斑狼疮：病例报告和文献综述

Case Reports in Dermatological Medicine Pub Date : 2024-02-16 DOI: 10.1155/2024/6748340

Trinh Thi Diem Nguyen, Trinh Ngoc To Chau, Phuong Thi Doan Vo, H. Nguyen

引用次数: 0